ATP-binding cassette transporters and drug resistance in cutaneous leishmaniasis
Leishmania spp. are intracellular protozoan parasites causative of visceral and cutaneous leishmaniasis. Recognized as a neglected tropical disease affecting millions of people around the world, this affliction represents a major public health problem. In Brazil, pentavalent antimony (SbV), the main...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971224003916 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841555735836622848 |
|---|---|
| author | Marina B.R. de Santana Giulia O. Miranda Lucas P. Carvalho |
| author_facet | Marina B.R. de Santana Giulia O. Miranda Lucas P. Carvalho |
| author_sort | Marina B.R. de Santana |
| collection | DOAJ |
| description | Leishmania spp. are intracellular protozoan parasites causative of visceral and cutaneous leishmaniasis. Recognized as a neglected tropical disease affecting millions of people around the world, this affliction represents a major public health problem. In Brazil, pentavalent antimony (SbV), the main therapy used to treat all clinical forms of leishmaniasis, has become increasingly associated with treatment failure. Many factors can influence leishmaniasis treatment outcome, including low expression aquaglyceroporin by the parasite and high activity of the ATP-binding cassette (ABC) transporters, efflux pumps whose activity has been associated with drug resistance in a variety of diseases. Current evidence suggests that some ABC transporters (e.g., MRP1 and MDR1) play a role in drug resistance in leishmaniasis. One way to potentially overcome SbV resistance may be a combined therapeutic strategy involving anti-Leishmania drugs administered together with ABC transporter inhibitors; however, toxicity poses a major challenge to the adoption of this approach. |
| format | Article |
| id | doaj-art-3d6cb688121640fa88e257978b38e75b |
| institution | Kabale University |
| issn | 1201-9712 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj-art-3d6cb688121640fa88e257978b38e75b2025-01-08T04:52:19ZengElsevierInternational Journal of Infectious Diseases1201-97122025-02-01151107315ATP-binding cassette transporters and drug resistance in cutaneous leishmaniasisMarina B.R. de Santana0Giulia O. Miranda1Lucas P. Carvalho2Laboratório de Pesquisas Clínicas (LAPEC), Gonçalo Moniz Institute (IGM), FIOCRUZ, Salvador, Bahia, BrazilLaboratório de Pesquisas Clínicas (LAPEC), Gonçalo Moniz Institute (IGM), FIOCRUZ, Salvador, Bahia, BrazilLaboratório de Pesquisas Clínicas (LAPEC), Gonçalo Moniz Institute (IGM), FIOCRUZ, Salvador, Bahia, Brazil; Serviço de Imunologia, Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil; Instituto Nacional de Ciências e Tecnologia - Doenças Tropicais (CNPq/MCT), Salvador, Bahia, Brazil; Corresponding author: Lucas P. Carvalho, Instituto Gonçalo Moniz - Fiocruz Bahia. Rua Waldemar Falcão, 121- Candeal, 40293-710, Salvador, Bahia, Brasil.Leishmania spp. are intracellular protozoan parasites causative of visceral and cutaneous leishmaniasis. Recognized as a neglected tropical disease affecting millions of people around the world, this affliction represents a major public health problem. In Brazil, pentavalent antimony (SbV), the main therapy used to treat all clinical forms of leishmaniasis, has become increasingly associated with treatment failure. Many factors can influence leishmaniasis treatment outcome, including low expression aquaglyceroporin by the parasite and high activity of the ATP-binding cassette (ABC) transporters, efflux pumps whose activity has been associated with drug resistance in a variety of diseases. Current evidence suggests that some ABC transporters (e.g., MRP1 and MDR1) play a role in drug resistance in leishmaniasis. One way to potentially overcome SbV resistance may be a combined therapeutic strategy involving anti-Leishmania drugs administered together with ABC transporter inhibitors; however, toxicity poses a major challenge to the adoption of this approach.http://www.sciencedirect.com/science/article/pii/S1201971224003916LeishmaniaMDRABC InhibitorABC transporterDrug resistance |
| spellingShingle | Marina B.R. de Santana Giulia O. Miranda Lucas P. Carvalho ATP-binding cassette transporters and drug resistance in cutaneous leishmaniasis International Journal of Infectious Diseases Leishmania MDR ABC Inhibitor ABC transporter Drug resistance |
| title | ATP-binding cassette transporters and drug resistance in cutaneous leishmaniasis |
| title_full | ATP-binding cassette transporters and drug resistance in cutaneous leishmaniasis |
| title_fullStr | ATP-binding cassette transporters and drug resistance in cutaneous leishmaniasis |
| title_full_unstemmed | ATP-binding cassette transporters and drug resistance in cutaneous leishmaniasis |
| title_short | ATP-binding cassette transporters and drug resistance in cutaneous leishmaniasis |
| title_sort | atp binding cassette transporters and drug resistance in cutaneous leishmaniasis |
| topic | Leishmania MDR ABC Inhibitor ABC transporter Drug resistance |
| url | http://www.sciencedirect.com/science/article/pii/S1201971224003916 |
| work_keys_str_mv | AT marinabrdesantana atpbindingcassettetransportersanddrugresistanceincutaneousleishmaniasis AT giuliaomiranda atpbindingcassettetransportersanddrugresistanceincutaneousleishmaniasis AT lucaspcarvalho atpbindingcassettetransportersanddrugresistanceincutaneousleishmaniasis |